Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; Received Expired Bivalent vaccine after 30-day Use By Date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received Expired Bivalent vaccine after 30-day Use By Date) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 050D22A) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Nov-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 29-Nov-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received Expired Bivalent vaccine after 30-day Use By Date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Received Expired Bivalent vaccine after 30-day Use By Date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Received Expired Bivalent vaccine after 30-day Use By Date).    This case is for adult patient 1 from 2 adult patients who received bivalent booster on 29-Nov-2022, as described by the reporter.  No concomitant medications were reported.  The vial could be either from individual vials or unbroken cartons and was of the size of 2.5 ml.  2 adult patients received bivalent booster on 29-Nov-2022 from the vial received as liquid on 05-Oct-2022 (thawed during transport in a cooler).  The vial did not undergo any temperature excursions.  Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2022-682176, US-MODERNATX, INC.-MOD-2022-682038, US-MODERNATX, INC.-MOD-2022-682093, US-MODERNATX, INC.-MOD-2022-682096, US-MODERNATX, INC.-MOD-2022-682097, US-MODERNATX, INC.-MOD-2022-682098, US-MODERNATX, INC.-MOD-2022-682100, US-MODERNATX, INC.-MOD-2022-682101, US-MODERNATX, INC.-MOD-2022-682103, US-MODERNATX, INC.-MOD-2022-682105, US-MODERNATX, INC.-MOD-2022-682111, US-MODERNATX, INC.-MOD-2022-682120, US-MODERNATX, INC.-MOD-2022-682134, US-MODERNATX, INC.-MOD-2022-682171, US-MODERNATX, INC.-MOD-2022-682173, US-MODERNATX, INC.-MOD-2022-682176 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-682176:Adult patient 2 from 2 adult patients received Bivalent booster on 29NOV2022 US-MODERNATX, INC.-MOD-2022-682038:Monovalent (Same reporter) US-MODERNATX, INC.-MOD-2022-682093:Monovalent (Same reporter) US-MODERNATX, INC.-MOD-2022-682096:Monovalent (Same reporter) US-MODERNATX, INC.-MOD-2022-682097:Monovalent (Same reporter) US-MODERNATX, INC.-MOD-2022-682098:Monovalent (Same reporter) US-MODERNATX, INC.-MOD-2022-682100:Monovalent (Same reporter) US-MODERNATX, INC.-MOD-2022-682101:Monovalent (Same reporter) US-MODERNATX, INC.-MOD-2022-682103:Monovalent (Same reporter) US-MODERNATX, INC.-MOD-2022-682105:Monovalent (Same reporter) US-MODERNATX, INC.-MOD-2022-682111:Monovalent (Same reporter) US-MODERNATX, INC.-MOD-2022-682120:Monovalent (Same reporter) US-MODERNATX, INC.-MOD-2022-682134:Monovalent (Same reporter) US-MODERNATX, INC.-MOD-2022-682171:Monovalent (Same reporter) US-MODERNATX, INC.-MOD-2022-682173:Monovalent (Same reporter) US-MODERNATX, INC.-MOD-2022-682176:Adult patient 1 from 2 adult patients received Bivalent booster on 29NOV2022